Search Result

Results for "

fibrotic diseases

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) Apoptosis (3) Autophagy (2) Bacterial (1) Bcl-2 Family (1) CDK (1) Cholecystokinin Receptor (1) Cyclin G-associated Kinase (GAK) (1) Discoidin Domain Receptor (2) ERK (1) Ferroptosis (1) Galectin (1) Glutathione S-transferase (1) GPR68 (1) GPR84 (1) Guanylate Cyclase (1) HBV (1) HCV (1) HCV Protease (1) HDAC (1) Hedgehog (1) HSP (1) Integrin (1) Interleukin Related (3) JAK (1) JNK (1) LPL Receptor (3) MAPKAPK2 (MK2) (1) Microtubule/Tubulin (1) Monoamine Oxidase (2) mTOR (1) NAMPT (1) NF-κB (2) P-glycoprotein (1) p38 MAPK (2) Palmitoyl Protein Thioesterase (PPT) (1) PARP (1) PDGFR (1) Phosphodiesterase (PDE) (1) PPAR (1) Reactive Oxygen Species (1) Reference Standards (1) RXFP Receptor (8) Src (1) TGF-beta/Smad (3) TGF-β Receptor (8) TNF Receptor (2) VEGFR (2) β-catenin (1)
By Research Areas:	Cancer (22) Cardiovascular Disease (12) Infection (3) Inflammation/Immunology (41) Metabolic Disease (8) Neurological Disease (4)

By Targets:

5-HT Receptor (1)

Apoptosis (3)

Autophagy (2)

Bacterial (1)

Bcl-2 Family (1)

CDK (1)

Cholecystokinin Receptor (1)

Cyclin G-associated Kinase (GAK) (1)

Discoidin Domain Receptor (2)

ERK (1)

Ferroptosis (1)

Galectin (1)

Glutathione S-transferase (1)

GPR68 (1)

GPR84 (1)

Guanylate Cyclase (1)

HBV (1)

HCV (1)

HCV Protease (1)

HDAC (1)

Hedgehog (1)

HSP (1)

Integrin (1)

Interleukin Related (3)

JAK (1)

JNK (1)

LPL Receptor (3)

MAPKAPK2 (MK2) (1)

Microtubule/Tubulin (1)

Monoamine Oxidase (2)

mTOR (1)

NAMPT (1)

NF-κB (2)

P-glycoprotein (1)

p38 MAPK (2)

Palmitoyl Protein Thioesterase (PPT) (1)

PARP (1)

PDGFR (1)

Phosphodiesterase (PDE) (1)

PPAR (1)

Reactive Oxygen Species (1)

Reference Standards (1)

RXFP Receptor (8)

Src (1)

TGF-beta/Smad (3)

TGF-β Receptor (8)

TNF Receptor (2)

VEGFR (2)

β-catenin (1)

By Research Areas:

Cancer (22)

Cardiovascular Disease (12)

Infection (3)

Inflammation/Immunology (41)

Metabolic Disease (8)

Neurological Disease (4)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-156552

DDR1/2 inhibitor-2	Discoidin Domain Receptor	Inflammation/Immunology Cancer
DDR1/2 inhibitor-2 (Example 31) is a DDR1/DDR2 inhibitor, with IC₅₀ values less than 100 nM. DDR1/2 inhibitor-2 can be used for research of cancer and fibrotic diseases .

HY-116100

(E/Z)-HA155	Phosphodiesterase (PDE)	Neurological Disease Inflammation/Immunology Cancer
(E/Z)-HA155 is a potent autotaxin (ATX) type I inhibitor. (E/Z)-HA155 can be used for researching cancer, fibrotic diseases, inflammation, pain and angiogenesis .

HY-162334

HYOU1-IN-1	Others	Inflammation/Immunology Cancer
HYOU1-IN-1 (Compound 33) is an inhibitor of hypoxia-upregulated protein 1 (HYOU1) with anti-inflammatory activity. HYOU1-IN-1 can be used in research on the regulation of fibroblast activation, chronic inflammation, and fibrotic diseases .

HY-172797

DDR Inhibitor 2	Discoidin Domain Receptor	Inflammation/Immunology
DDR Inhibitor 2 (compound 5a) is a discoidin domain receptor (DDR) inhibitor with an IC₅₀ of 0.125 μM. DDR Inhibitor 2 can be used for study of fibrotic diseases .

HY-138453

ACT-1016-0707 LPA1 receptor antagonist 2	LPL Receptor	Inflammation/Immunology
ACT-1016-0707 (Compound 49) is an orally active and selective LPA1 receptor antagonist. ACT-1016-0707 can be used for the research of fibrotic diseases .

HY-153730

Hedgehog IN-5	Hedgehog	Inflammation/Immunology
Hedgehog IN-5 is an orally active small molecule inhibitor of the hedgehog pathway. Hedgehog IN-5 can be used for the research of fibrotic disease .

HY-P4040

Ac-D-DGla-LI-Cha-C	HCV Protease	Infection Neurological Disease Metabolic Disease Inflammation/Immunology Cancer
Ac-D-DGla-LI-Cha-C is a potent HCV protease inhibitor peptide. Ac-D-DGla-LI-Cha-C can be used for the research of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases .

HY-142698

SGC agonist 2	Guanylate Cyclase	Cardiovascular Disease
SGC agonist 2 is a potent agonist of soluble guanylate cyclase (SGC). Soluble guanylate cyclase is a key signal transduction enzyme in the NO-sGC-cGMP signaling pathway. SGC agonist 2 has the potential for the research of cardiovascular disease (heart failure, pulmonary hypertension, angina, myocardial infarction) and fibrotic diseases (renal fibrosis, systemic sclerosis) (extracted from patent WO2021219088A1, compound 031) .

HY-151281

ALK5-IN-31	TGF-β Receptor	Cancer
ALK5-IN-31 (compound Ex-08) is a selective ALK-5 inhibitor (IC₅₀≤10 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-31 has the potential to inhibit growth of tumour in vivo. ALK5-IN-31 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .

HY-151275

ALK5-IN-28	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-28 (compound Ex-05) is a selective ALK-5 inhibitor (IC₅₀≤10 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-28 has the potential to inhibit growth of tumour in vivo. ALK5-IN-28 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .

HY-151282

ALK5-IN-32	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-32 (compound EX-09) is a selective ALK-5 inhibitor (10 nM<IC₅₀<100 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-32 has the potential to inhibit growth of tumour in vivo. ALK5-IN-32 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis .

HY-147243

Ansornitinib ANG-3070	VEGFR PDGFR	Cardiovascular Disease Inflammation/Immunology
Ansornitinib is an orally active dual kinase inhibitor that inhibits platelet-derived growth factor receptor (PDGFR) and vascular endothelial growth factor receptor (VEGFR2). Ansornitinib can be used as an antifibrotic agent in lung, liver, kidney, and gastrointestinal fibrotic diseases .

HY-142949

ALK5-IN-7	TGF-β Receptor	Inflammation/Immunology Cancer
ALK5-IN-7 is a potent inhibitor of ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5-IN-7 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 4) .

HY-142950

ALK5-IN-6	TGF-β Receptor	Inflammation/Immunology Cancer
ALK5-IN-6 is a potent inhibitor of ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5-IN-6 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 1) .

HY-110279

Ogerin 1 Publications Verification	GPR68	Neurological Disease
Ogerin is a selective GPR68 positive aliasing modulator (PAM) (pEC₅₀=6.83) with a moderate antagonistic effect on A_2A (K_i=220 nM). Ogerin inhibits the fear conditioning reflex in mice and also inhibits TGF-β-induced myofibroblast differentiation of fibroblasts from multiple organ systems. Ogerin can be used in the studies of fibrotic diseases and neurological disorders .

HY-113604

Pentabromopseudilin	TGF-β Receptor	Cancer
Pentabromopseudilin (PBrP) is a marine antibiotic isolated from the marine bacteria Pseudomonas bromoutilis and Alteromonas luteoviolaceus. PBrP exhibits antimicrobial, anti-tumour and phytotoxic activities. PBrP is a reversible and allosteric inhibitor of myosin Va (MyoVa). PBrP also is a potent inhibitor of transforming growth factor-β (TGF-β) activity. PBrP can be used for the research of fibrotic diseases and cancer .

HY-15147

XAV-939 Maximum Cited Publications 142 Publications Verification	β-catenin PARP	Cancer
XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC₅₀ values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation .

HY-141845

S1P2 antagonist 1	LPL Receptor	Others
S1P2 antagonist 1 is an orally bioavailable S1P2 antagonist against fibrotic diseases.

HY-P3446A

Big Gastrin I (human) TFA	Cholecystokinin Receptor	Infection Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
Big Gastrin I, human (TFA) is a gastrointestinal hormone consisting of 34 amino acids. Big Gastrin I, human (TFA) can be used as a potential substance for the study of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurological diseases or cardiovascular diseases .

HY-P991488

BI-765423	Interleukin Related	Inflammation/Immunology
BI-765423 is a human monoclonal antibody (mAb) targeting IL-11. BI-765423 can be used in fibrotic diseases research .

HY-P990007

Tulisokibart PRA023; PRA-023	TNF Receptor	Inflammation/Immunology
Tulisokibart (PRA023) is a humanized IgG1-κ monoclonal antibody. Tulisokibart targets to TNFSF15/TL1A. Tulisokibart can be used to study a variety of inflammatory/fibrotic diseases, such as Crohn's Disease (CD) and ulcerative colitis .

HY-173235

Galectin-3-IN-6	Galectin	Cardiovascular Disease Inflammation/Immunology Cancer
Galectin-3-IN-6 (Compound 12) is an orally active inhibitor of galectin-3 (Gal-3), with an IC₅₀ value of 12 nM and a K_d value of 13 nM for Gal-3. In a mouse model of acute liver injury and fibrosis induced by CCl4, Galectin-3-IN-6 can significantly reduce the levels of fibrosis markers collagen-1 and α-smooth muscle actin (αSMA) by 64% and 71%, respectively, showing significant anti-fibrotic activity. Galectin-3-IN-6 can be used in the research of fibrotic diseases, cancer, and cardiovascular diseases .

HY-139853

BMS-986278 1 Publications Verification	LPL Receptor	Others
BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with K_bs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases .

HY-137978

Ezurpimtrostat GNS561	Autophagy	Metabolic Disease Inflammation/Immunology Cancer
Ezurpimtrostat (compound 2-2) is a potent and orally active anti-fibrotic agent. Ezurpimtrostat can be used for the research of fibrosis, cancer, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases (extracted from patent WO2020048694 A1) .

HY-168990

Ontunisertib	TGF-β Receptor	Metabolic Disease Cancer
Ontunisertib (Example 26) is an inhibitor of TGFβ receptor I/ALK5 (TGFβRI/ALK5), with IC₅₀ values ranging from 100 to 500 nM for TGFβRI and an IC₅₀ value of ≤100 nM for ALK5. Ontunisertib can be used in research on gastrointestinal diseases, as well as diseases and cancers related to fibrotic conditions in the skin and eyes .

HY-P991489

ENx-108A	Interleukin Related	Inflammation/Immunology
ENx-108A is a human IgG4 monoclonal antibody (mAb) targeting IL-11. BI-765423 can be used in fibrotic diseases research. Recommended isotype control: Human IgG4 kappa, Isotype Control (HY-P99003) .

HY-137978A

Ezurpimtrostat hydrochloride 1 Publications Verification GNS561 hydrochloride	Palmitoyl Protein Thioesterase (PPT)	Metabolic Disease Inflammation/Immunology Cancer
Ezurpimtrostat hydrochloride (compound 2-3) is a potent and orally active anti-fibrotic agent. Ezurpimtrostat hydrochloride reduces significantly the liver fibrosis in DEN (diethyl nitrosamine) cirrhotic rat model. Ezurpimtrostat hydrochloride can be used for the research of fibrosis, cancer, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases .

HY-172258

5-HT2B antagonist-2	5-HT Receptor	Cancer
5-HT2B antagonist-2 (Compound 19c) is a 5HT_2B receptor antagonist with an IC₅₀ of 1.09 nM. 5-HT2B antagonist-2 can downregulate the expression of fibrosis-related genes α-SMA, Timp1, Col1a1, and Col3a1, and significantly reduce the deposition of fibrosis, thereby reducing the fibrotic area and inhibiting the fibrotic process in CCl4-induced liver fibrosis mouse models. 5-HT2B antagonist-2 can be used in the study of immune inflammatory-related diseases, particularly in the research of pulmonary fibrosis diseases .

HY-126397

MnTBAP chloride 1 Publications Verification	NF-κB	Inflammation/Immunology
MnTBAP chloride is a superoxide dismutase (SOD) mimetic and peroxynitrite scavenger. MnTBAP chloride is a manganic porphyrin complex and has anti-oxidative property. MnTBAP chloride mediates anti-inflammatory effects through upregulation of BMPR-II and inhibition of the NFκB signaling. MnTBAP chloride has the potential for the fibrotic response in chronic kidney diseases (CKDs) research .

HY-P2797

Chitinase, Serratia marcescens AMCase, Serratia marcescens	Bacterial	Metabolic Disease Inflammation/Immunology
Chitinase, Serratia marcescens (EC 3.2.1.14) has partial lysozyme activity and is widely found in bacteria, fungi, animals and some plants. Chitinase belongs to the glycosyl hydrolase family. Chitinase catalyzes chito-oligosaccharide hydrolysis. Chitinases also can serve as prognostic biomarkers of disease progression. Chitinase can be used in the research of pathogenesis of various human fibrotic and inflammatory disorders, particularly those of the lung (idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, sarcoidosis, and asthma) and the gastrointestinal tract (inflammatory bowel diseases (IBDs) and colon cancer) .

HY-P3412

MMI-0100	MAPKAPK2 (MK2)	Inflammation/Immunology
MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression. MMI-0100 suppresses fibrotic processes such as vein graft disease .

HY-129171

TGFBR1-IN-1	TGF-β Receptor	Inflammation/Immunology Cancer
TGFBR1-IN-1 is an ALK5 inhibitor extracted from patent WO2018004290A1, Compound 33, has an IC₅₀ of 10-100 nM .

HY-151100

GPR84 antagonist 3	GPR84	Inflammation/Immunology
GPR84 antagonist 3 (compound 42) is a potent GPR84 (G-protein-coupled receptor 84) antagonist. GPR84 antagonist 3 inhibits GTPγS, with a pIC₅₀ of 8.28. GPR84 antagonist 3 has a favorable pharmacokinetic profile suitable .

HY-47888

PLN-1474	Integrin	Inflammation/Immunology
PLN-1474 (compound 1) is an orally active and selective ανβ1 integrin inhibitor with an IC50 value of <50 nM. PLN-1474 reduces levels of pSMAD3/SMAD3 in liver, hepatic collagen gene expression and hepatic OHP concentration in liver fibrosis mouse model. PLN-1474 can be used for the research of preventing, delaying or researching a fibrotic or cirrhotic disease or disorder.

HY-107422A

Lenumlostat hydrochloride PAT-1251 hydrochloride; GB2064 hydrochloride	Monoamine Oxidase	Inflammation/Immunology
PAT-1251 Hydrochloride is a potent, selective and oral lysyl oxidase-like 2 (LOXL2) inhibitor, with IC₅₀s of 0.71 and 1.17 μM for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (IC₅₀s, 0.10, 0.12, and 0.16 μM, respectively). PAT-1251 Hydrochloride is used in the research of fibrotic diseases.

HY-107422

Lenumlostat 1 Publications Verification PAT-1251; GB2064	Monoamine Oxidase	Inflammation/Immunology
PAT-1251 is a potent, selective and oral lysyl oxidase-like 2 (LOXL2) inhibitor, with IC₅₀s of 0.71 and 1.17 μM for hLOXL2 and hLOXL3, respectively, and also potently inhibits mouse, rat, and dog LOXL2 (IC₅₀s, 0.10, 0.12, and 0.16 μM, respectively); PAT-1251 is used in the research of fibrotic diseases .

HY-144111

PPARα/δ agonist 1	PPAR	Inflammation/Immunology
PPARα/δ agonist 1 is a potent PPARα/PPARδ dual agonist (PPARα EC₅₀=7.0 nM; PPARδ EC₅₀=8.4 nM). PPARα/δ agonist 1 is a high selectivity over PPARγ (PPARγ EC₅₀=1316.1 nM). PPARα/δ agonist 1 has the potential for the research of nonalcoholic steatohepatitis .

HY-169940

Fibrostat	HDAC	Inflammation/Immunology
Fibrostat (Compound 5n) is a selective HDAC6 inhibitor that exerts antifibrotic effects by inhibiting HDAC6 activity, with an IC₅₀ value of 63 nM. It also exhibits good selectivity over HDAC1, HDAC3, HDAC5, HDAC8, HDAC10, and HDAC11. Fibrostat significantly downregulates fibrotic markers (fibronectin and collagen 1) in fibroblasts. Additionally, Fibrostat demonstrated no toxicity in rat-perfused heart and zebrafish larvae models. Fibrostat shows potential for research into fibrosis-related diseases .

HY-156539

RXFP1 receptor agonist-4	RXFP Receptor	Cardiovascular Disease Inflammation/Immunology
RXFP1 receptor agonist-4 (Example 268) is a RXFP1 receptor agonist. RXFP1 receptor agonist-4 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC₅₀ value of 4.9 nM .

HY-156536

RXFP1 receptor agonist-1	RXFP Receptor	Cardiovascular Disease Inflammation/Immunology
RXFP1 receptor agonist-1 (Example 2 peak2) is a RXFP1 receptor agonist. RXFP1 receptor agonist-1 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC₅₀ value of 300 nM .

HY-156541

RXFP1 receptor agonist-6	RXFP Receptor	Cardiovascular Disease Inflammation/Immunology
RXFP1 receptor agonist-6 (Example 7) is a RXFP1 receptor agonist. RXFP1 receptor agonist-6 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC₅₀ value of 12 nM .

HY-P99020

Fresolimumab 1 Publications Verification GC1008	TGF-beta/Smad	Metabolic Disease Inflammation/Immunology Cancer
Fresolimumab (GC1008) is a human monoclonal antibody against TGF-β that neutralizes all mammalian active subtypes of TGF-β. The binding affinity of Fresolimumab to TGF-β2 is 1.8 nM. Fresolimumab improves Bleomycin (HY-108345)-induced acute lung injury. Fresolimumab radiolabeled with ⁸⁹Zr can be used for PET analysis of TGF-β expression, antibody uptake and organ distribution. Fresolimumab can be used in the study of cancer, osteogenesis imperfecta, fibrosis and kidney disease .

HY-156543

RXFP1 receptor agonist-8	RXFP Receptor	Cardiovascular Disease Inflammation/Immunology
RXFP1 receptor agonist-8 (Example 2) is a RXFP1 receptor agonist. RXFP1 receptor agonist-8 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC₅₀ value of 1.8 nM .

HY-156540

RXFP1 receptor agonist-5	RXFP Receptor	Inflammation/Immunology
RXFP1 receptor agonist-5 (Example 98) is a RXFP1 receptor agonist. RXFP1 receptor agonist-5 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC₅₀ value of 1.3 nM .

HY-156538

RXFP1 receptor agonist-3	RXFP Receptor	Inflammation/Immunology
RXFP1 receptor agonist-3 (Example 223) is a RXFP1 receptor agonist. RXFP1 receptor agonist-3 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC₅₀ value of 2 nM .

HY-156537

RXFP1 receptor agonist-2	RXFP Receptor	Cardiovascular Disease Inflammation/Immunology
RXFP1 receptor agonist-2 (Example 124) is a RXFP1 receptor agonist. RXFP1 receptor agonist-2 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC₅₀ value of 1 nM .

HY-156542

RXFP1 receptor agonist-7	RXFP Receptor	Cardiovascular Disease Inflammation/Immunology
RXFP1 receptor agonist-7 (Example 2) is a RXFP1 receptor agonist. RXFP1 receptor agonist-7 stimulates cAMP production in HEK293 cells stably expressing human RXFP1, with an EC₅₀ value of 4.2 nM .

HY-N0671

Rhapontin 1 Publications Verification Rhaponiticin	Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .

HY-N0671R

Rhapontin (Standard) Rhaponiticin (Standard)	Reference Standards Apoptosis	Cardiovascular Disease Metabolic Disease Inflammation/Immunology Cancer
Rhapontin (Standard) is the analytical standard of Rhapontin (HY-N0671). This product is intended for research and analytical applications. Rhapontin (Rhaponiticin) is an orally aactive SIRT1 agonist and AMPK activator with anti-inflammatory and anti-fibrotic activities. Rhapontin inhibits NLRP3 inflammasome activation by activating SIRT1 and inhibits TGF-β/Smad signaling via the AMPK pathway. Rhapontin reduces intestinal and lung inflammation, inhibits fibroblast differentiation and extracellular matrix deposition, and enhances tight junction protein expression to repair epithelial barriers. Rhapontin can be used in the study of inflammatory bowel diseases (such as ulcerative colitis) and pulmonary fibrosis .

HY-18303

AMG-47a 3 Publications Verification	Src VEGFR p38 MAPK JAK	Inflammation/Immunology
AMG-47a is an orally active, ATP-competitive Lck inhibitor (IC₅₀=0.2 nM). AMG-47a inhibits VEGF2, p38α, p38α, Jak3, MLR, and IL-2 with IC₅₀ of 1 nM, 3 nM, 72 nM, 30 nM, and 21 nM, respectively. AMG-47a reduces T cell activation and the production of cytokines such as TGF-β, exerting anti-inflammatory and anti-fibrotic activities. AMG-47a can be used in the research of autoimmune diseases, pulmonary fibrosis, and KRAS mutation-associated cancers[1][2][3].

Cat. No.	Product Name	Target	Research Area